Is COVID Still Out There? Current Risks Explained

SARS-CoV-2, the virus that causes COVID-19, is still circulating widely and continues to cause serious illness and death. The pandemic emergency declarations ended in 2023, but that reflected a shift in how governments manage the virus, not the virus’s disappearance. New variants emerge regularly, hospitalizations spike each winter and summer, and the virus remains one of the leading infectious causes of death in many countries. The risks have changed shape since 2020, though, and understanding what those risks look like now matters more than ever.

How We Know COVID Is Still Spreading

One of the biggest changes since the early pandemic is how we track the virus. Fewer people get tested at clinics or report results to public health agencies, which means traditional case counts understate reality by a wide margin. The surveillance system that has picked up the slack is wastewater monitoring. Sewage sampling detects fragments of SARS-CoV-2 shed by infected people, whether or not those people ever take a test or visit a doctor. This approach captures infections across an entire community at once and often picks up surges before hospitals start filling up.

The CDC’s national wastewater dashboard tracks viral levels at hundreds of sampling sites across the United States. The data consistently show that SARS-CoV-2 never drops to zero. Viral concentrations rise and fall in a wave pattern, typically peaking in winter and again in mid-to-late summer. During troughs, the virus is still present at detectable levels in most regions. Wastewater data can signal rising or falling infection rates ahead of clinical reports and hospitalizations, making it one of the most reliable real-time indicators of where things stand.¹

If you have wondered whether COVID quietly vanished because it left the daily news cycle, the wastewater tells a clear story: it did not. The difference now is that most people have some degree of immunity from prior infection, vaccination, or both, which blunts the proportion of infections that become severe. But “blunted” is not “eliminated,” and for certain groups the risk of a bad outcome remains substantial.

The Virus Keeps Evolving

SARS-CoV-2 mutates quickly, and the variants circulating today look considerably different from the strains that swept through the population in 2020 and 2021. The Omicron lineage took over globally in late 2021 and has continued branching into subvariants. Each new branch tends to carry mutations that help it slip past antibodies generated by vaccines or previous infections.

A 2025 study in Nature Communications examined several subvariants descended from JN.1, including KP.2, KP.3, and KP.3.1.1. The researchers found that KP.3.1.1, in particular, carried a deletion in its spike protein that gave it an additional layer of immune evasion, reducing the effectiveness of antibodies by roughly 1.8-fold compared to the already evasive KP.3 subvariant.² That may sound abstract, but the practical implication is straightforward: the virus is getting better at reinfecting people who have been vaccinated or previously infected. Each new dominant variant is slightly more adept at dodging your immune defenses than the last one was.

This is why COVID waves keep happening even in highly vaccinated populations. Immunity does not disappear overnight, but it erodes as the virus’s surface proteins drift further from what your immune system was trained to recognize. Updated vaccines are designed to close that gap, but the virus moves fast enough that each vaccine update is playing catch-up to some degree.

Who Faces the Highest Risk Now

The risk of severe COVID-19 has never been evenly distributed, and that remains true. Older adults and people with multiple chronic health conditions face dramatically higher odds of hospitalization, ICU admission, and death compared to younger, healthier individuals. A large U.S. study comparing outcomes across populations found that older age and a greater number of chronic medical conditions led to a significantly higher proportion of severe COVID-19 outcomes and higher healthcare costs.³

Immunocompromised individuals are in a particularly difficult position. People on chemotherapy, organ transplant recipients taking immunosuppressive drugs, and those with conditions like advanced HIV or certain autoimmune diseases often mount weaker immune responses to vaccines. For these groups, a single COVID infection can be prolonged and severe, and they are more likely to develop complications that land them in the hospital.

But “high risk” is not limited to the obviously vulnerable. Conditions that raise COVID risk include diabetes, chronic kidney disease, obesity, heart failure, and chronic lung disease. Many adults in their 40s and 50s carry one or more of these conditions without thinking of themselves as being in a risk category. If you have a couple of chronic conditions and you are over 50, your risk profile for COVID is meaningfully different from a healthy 30-year-old’s, even if you have been vaccinated.

How Well the Current Vaccines Work

Updated COVID vaccines are reformulated each year to better match the circulating variants, similar to how flu vaccines are updated annually. The 2024-2025 COVID vaccines targeted more recent Omicron-lineage variants. The key question most people have is whether these vaccines are still worth getting, especially after multiple prior doses or infections.

A study published in JAMA Network Open estimated the effectiveness of the 2024-2025 COVID vaccines among adults with healthy immune systems. Overall, the vaccines reduced the risk of COVID-related hospitalization by about 40%. Against the most severe outcomes, specifically being put on a ventilator or dying, effectiveness jumped to roughly 79%.⁴

That 40% figure for hospitalization prevention might seem modest, and it is lower than the eye-popping efficacy numbers from the original clinical trials in 2020. But context matters. The population today has a patchwork of immunity from prior infections and older vaccine doses, so the updated vaccine is adding protection on top of an existing baseline. And the nearly 80% effectiveness against ventilation or death is a strong signal that the vaccines remain very good at preventing the worst outcomes, even if they cannot stop every infection or mild illness.

For people who are immunocompromised, effectiveness is generally lower because their immune systems have a harder time building a robust response. Additional doses and combination strategies are sometimes recommended for these groups, and anyone in this category should talk with their doctor about timing and dosing.

Long COVID and the Risk of Lasting Symptoms

One of the most unsettling aspects of COVID that persists is long COVID, the collection of symptoms that can linger for weeks, months, or longer after the initial infection clears. Fatigue, brain fog, shortness of breath, heart palpitations, and exercise intolerance are among the most commonly reported problems. Long COVID can affect people who had mild initial infections as well as those who were hospitalized.

Vaccination appears to offer some protection against developing long COVID. A systematic review and meta-analysis that pooled data from multiple studies found that people who had received two doses of a COVID vaccine were significantly less likely to develop long COVID compared to unvaccinated individuals. The vaccinated group had roughly 36% lower odds of developing prolonged symptoms.⁵ That is a meaningful reduction, though it also means vaccination does not eliminate the risk entirely.

Research into long COVID is still evolving. There are ongoing debates about whether certain variants are more or less likely to cause persistent symptoms, whether reinfections carry cumulative risk, and what treatments might help people already living with it. What is clear is that long COVID is not a relic of the early pandemic. It continues to develop in people infected with current variants, and it remains one of the strongest arguments for taking steps to reduce your chances of getting infected in the first place.

Antiviral Treatments and What They Can Do

If you do get COVID, treatment options exist that can meaningfully reduce your risk of a bad outcome. The most widely used antiviral is nirmatrelvir/ritonavir, commonly known by its brand name Paxlovid. It was originally authorized during the Delta and early Omicron waves, but its effectiveness has been studied extensively in the current landscape of widespread vaccination, prior infection, and newer variants.

A large meta-analysis that pooled results from 47 studies covering nearly 11 million patients found that Paxlovid roughly halved the risk of hospitalization. For all-cause hospitalization, the risk was reduced by about 46%, and for COVID-specific hospitalization, the reduction was about 55%.⁶ These results held even in a population where most people already had some immunity, which suggests the drug provides a real additional layer of protection on top of what your immune system can do on its own.

Paxlovid is most effective when started within the first five days of symptom onset. It is typically prescribed for people at higher risk of severe disease, including older adults and those with underlying health conditions. One common complaint is “Paxlovid rebound,” where symptoms temporarily return after finishing the course. Rebound is generally mild and self-limiting, but it can be frustrating. The drug also interacts with a long list of other medications, which is why a prescriber needs to review what you are taking before writing the prescription.

For people who cannot take Paxlovid, remdesivir given by IV infusion within the first week of illness is another option, though it requires a visit to an infusion center. Molnupiravir is a third antiviral, but its effect sizes have been less impressive in studies, and it is not as widely recommended. The point is that treatment is available and effective, but it works best when accessed quickly. Waiting until you are severely ill to seek care misses the window when antivirals do the most good.

Reinfections and Cumulative Exposure

A question that gets less public attention than it should is what happens when you get COVID more than once. Reinfections are common now. The combination of waning immunity and evolving variants means that most people can be reinfected after several months, sometimes sooner. The immune evasion capacity of newer variants like KP.3.1.1 makes reinfection even more likely.²

Each reinfection tends to be milder than the first for most healthy people, in part because the immune system retains some memory even if antibodies have declined. But “milder on average” is a population-level statement, and individual experiences vary. Some people have a worse second or third bout than their first, particularly if their health status has changed or if they encounter a substantially different variant. There is also emerging concern, though not yet settled science, about whether repeated infections carry cumulative risks for certain organ systems, particularly the heart and the brain. Some researchers have observed elevated cardiovascular event rates in the months following a COVID infection, and the question of whether each additional infection adds incremental damage remains an active area of study.

For practical purposes, the takeaway is that having had COVID before does not make you bulletproof against future infections. Natural immunity provides real but incomplete and temporary protection, much like vaccine-derived immunity. The two together offer the strongest defense, but neither is a permanent shield.

Practical Steps That Still Make a Difference

The tools available for reducing your COVID risk have not changed much since 2022, but the context in which you use them has. Staying up to date on vaccination remains the single most impactful thing most people can do, especially for those over 50 or with chronic health conditions. The updated vaccines reduce both hospitalization and the risk of the worst outcomes.⁴

Rapid home tests still work against current variants, though their sensitivity is slightly lower in the first day or two of symptoms. Testing when you feel sick, especially before visiting elderly relatives or attending events with vulnerable people, is a straightforward courtesy that costs almost nothing. If you test positive and are in a higher-risk group, contacting a healthcare provider quickly to discuss antiviral treatment can cut your hospitalization risk substantially.⁶

High-quality masks, particularly N95 or KN95 respirators, still provide strong personal protection in crowded indoor settings. Most people have stopped wearing them, and there is no broad public health mandate to bring them back. But in high-risk situations, such as a hospital visit, a long flight during a surge, or spending time indoors during a local wastewater spike, wearing a good mask is one of the most effective individual actions you can take. Checking your regional wastewater data through the CDC’s dashboard gives you a rough sense of how much virus is circulating in your area at any given time, which can inform decisions about when extra precautions are worthwhile.¹

How COVID Compares to Other Respiratory Threats Now

People often ask whether COVID has become “just another flu.” The comparison is understandable but misleading. Seasonal influenza kills tens of thousands of Americans in a bad year, and COVID’s annual death toll has been consistently higher since the pandemic began, even in years with widespread vaccination and prior infection. COVID also causes long-term complications at a rate that influenza rarely matches.

That said, the gap has narrowed. The average COVID infection in a healthy, vaccinated person in 2025 is a very different experience from an infection in an unvaccinated person in 2020. Most infections are now mild to moderate, resolving within a week or two. The virus has not become inherently less dangerous through some biological softening. Rather, population immunity has made the average encounter less severe. If that immunity were stripped away, as it effectively is in immunocompromised individuals, the virus would still be capable of causing devastating illness.

RSV (respiratory syncytial virus) is another respiratory pathogen that now has vaccines available for older adults and pregnant individuals. In practical terms, the respiratory virus landscape has shifted toward a model where multiple serious pathogens circulate simultaneously each fall and winter, and staying protected means considering updated vaccines for COVID, flu, and RSV rather than treating any one of them as the sole threat. The combined burden of all three viruses on hospitals during peak season is a recurring concern for healthcare systems, particularly when surges overlap.